Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, noviembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
BioLine Rx Ltd
BLRX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.9639
-0.0961
-9.07%
al cierre: Nov 20, 4:00 PM EST
$0.9900
0.0261
2.71%
After hour: 5:27 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Informe de acciones
Ganancias:
Los beneficios de Q3 2026 mañana en lun nov 23rd antes de la apertura del mercado
Conferencia telefónica:
Conferencia telefónica programada para mañana a las 8:30 a. m.
Haz clic para ver el webcast
BioLine Rx Financials
BioLine Rx (BLRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BioLine Rx Q2 Sales $294.000K Miss $500.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $294.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 41.20 percent. This is a 3.29 percent decrease over sales of $304.000 thousand
Benzinga Newsdesk
PRO
BioLine Rx Q1 Sales $477.000K Beat $343.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $477.000 thousand which beat the analyst consensus estimate of $343.000 thousand by 39.07 percent. This is a 87.06 percent increase over sales of $255.000 thousand
Benzinga Newsdesk
PRO
BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.54) by 37.04 percent. The company reported quarterly sales of $194.000 thousand which missed the
Benzinga Newsdesk
PRO
BioLine Rx Q4 Sales $194.000K Miss $651.598K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly sales of $194.000 thousand which missed the analyst consensus estimate of $651.598 thousand by 70.23 percent. This is a 98.35 percent decrease over sales of $11.749 million
Benzinga Newsdesk
Earnings Scheduled For March 23, 2026
Benzinga Insights
PRO
BioLine Rx Q3 EPADS $(0.22) Beats $(1.20) Estimate, Sales $427.000K Miss $990.000K Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(1.20) by 81.67 percent. This is a 214.29 percent decrease over losses of $(0.07) per share from the
Benzinga Newsdesk